J Gynecol Oncol.  2019 Mar;30(2):e19. 10.3802/jgo.2019.30.e19.

Role of adjuvant chemotherapy in the management of non-granulosa cell ovarian sex cord-stromal tumors

Affiliations
  • 1Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. dimitrios.nasioudis@uphs.upenn.edu
  • 2Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • 3Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.

Abstract


OBJECTIVE
To investigate the role of adjuvant chemotherapy (CT) in the management of ovarian non-granulosa cell (GC) sex cord-stromal tumors (SCSTs).
METHODS
The National Cancer Database was accessed and patients diagnosed between 2004 and 2013 with a malignant non-GC SCST were selected. Overall survival (OS) was evaluated with Kaplan-Meier curves and compared with the log-rank test. Multivariate survival analysis was performed with Cox regression. Factors associated with the administration of CT were evaluated with the chi-square test and binary logistic regression.
RESULTS
A total of 391 patients were identified. The majority had a Sertoli-Leydig cell tumor (SLCT) (73.2%) and early stage disease (84.8%). A total of 203 (51.9%) patients received CT. Advanced disease stage, younger age, high-grade histology, White race, large tumor size and SLCT histology were associated with administration of CT. For patients with early stage disease, there was no difference in OS between those who did (n=134) and did not receive CT (n=157), p=0.40; 5-year OS rates were 81.7% and 84.6%, respectively. No mortality benefit was observed (hazard ratio=0.73; 95% confidence interval=0.38-1.4) after controlling for tumor histology. Median OS of women with advanced stage disease who received CT (n=41) was 34.96 months compared to 15.51 months for those who did not (n=11), p=0.013.
CONCLUSIONS
Adjuvant CT was associated with improved survival for patients with advanced stage non-GC SCSTs. No clear benefit was found for those with early stage disease.

Keyword

Ovarian Cancer; Chemotherapy; Sex Cord-stromal Tumor

MeSH Terms

Chemotherapy, Adjuvant*
Continental Population Groups
Drug Therapy
Female
Humans
Logistic Models
Mortality
Ovarian Neoplasms
Sertoli-Leydig Cell Tumor
Sex Cord-Gonadal Stromal Tumors*
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr